AGNPF Stock - Algernon Pharmaceuticals Inc.
Unlock GoAI Insights for AGNPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-50,398 | $-34,936 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,305,000 | $-5,018,000 | $-6,118,000 | $-9,841,000 | $-9,397,000 |
| Net Income | $-503,000 | $-6,781,000 | $-6,054,000 | $-7,734,000 | $-8,538,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.03 | $-0.45 | $-0.87 | $-1.24 | $-2.42 |
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Visit WebsiteEarnings History & Surprises
AGNPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | — | — | — | — |
Q3 2025 | Jul 30, 2025 | — | — | — | — |
Q2 2025 | Apr 29, 2025 | — | $-0.01 | — | — |
Q1 2025 | Jan 29, 2025 | — | $-0.01 | — | — |
Q4 2024 | Dec 23, 2024 | — | $-0.01 | — | — |
Q3 2024 | Jul 29, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 24, 2024 | — | $0.05 | — | — |
Q2 2024 | Apr 16, 2024 | — | $-0.04 | — | — |
Q4 2023 | Dec 29, 2023 | — | $-0.02 | — | — |
Q3 2023 | Aug 31, 2023 | $-0.10 | $-0.12 | -22.7% | ✗ MISS |
Q2 2023 | May 31, 2023 | $-0.07 | $-0.08 | -4.9% | ✗ MISS |
Q1 2023 | Jan 30, 2023 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q4 2022 | Nov 25, 2022 | $-0.17 | $0.30 | +276.5% | ✓ BEAT |
Q3 2022 | Jul 29, 2022 | $-0.23 | $0.12 | +152.2% | ✓ BEAT |
Q2 2022 | May 31, 2022 | — | $-0.09 | — | — |
Q2 2022 | Apr 26, 2022 | — | $-0.22 | — | — |
Q4 2021 | Nov 25, 2021 | $-0.75 | $-0.08 | +89.3% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $-0.50 | $-0.25 | +50.0% | ✓ BEAT |
Q2 2021 | Apr 29, 2021 | $-0.75 | $-0.50 | +33.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about AGNPF
What is AGNPF's current stock price?
What is the analyst price target for AGNPF?
What sector is Algernon Pharmaceuticals Inc. in?
What is AGNPF's market cap?
Does AGNPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AGNPF for comparison